在老鼠肌管中发现了带有两个氨基功能的光环,作为SHIP2抑制剂,具有胰岛素敏感作用
Phei Ching Lim1, Beow Keat Yap1, Yi Juin Tay1
1School of Pharmaceutical Sciences, Universiti Sains Malaysia Minden 11800 Penang Malaysia chongyew@usm.my +604 653 4086.
RSC medicinal chemistry
|June 24, 2024
概括
新的奥龙化合物被开发为SHIP2的小分子抑制剂 (SH2域含有内醇5-酸酶2). 这些新型SHIP2抑制剂增强葡萄糖吸收,显示出作为口服胰岛素敏感剂的潜力.
科学领域:
- 药用化学 医学化学
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- SHIP2 (SH2域含有内醇5-酸酶2) 是胰岛素信号的关键调节者.
- 用小分子抑制剂向SHIP2提供了一种改善胰岛素敏感性的治疗策略.
- 迄今为止,很少有类似药物的SHIP2抑制剂被确定.
研究的目的:
- 合成和评估新型奥龙衍生物作为潜在的SHIP2抑制剂.
- 研究基于光子的SHIP2抑制剂的作用机制和结构-活性关系.
- 在细胞模型中评估化合物在增强葡萄糖吸收方面的有效性.
主要方法:
- 合成了一系列包含已知SHIP2抑制剂结构特征的极光化合物.
- 在体外酶分析测试以确定SHIP2抑制活性.
- 分子动力学模拟以阐明结合模式和机制.
- 基于细胞的测试使用老鼠肌管来测量葡萄糖吸收和Akt酸化.
- 卡科2细胞单层透性测试.
主要成果:
- 三种极光化合物在15-50μM范围内显示出SHIP2的抑制.
- 最佳的抑制需要在光环结构的A环和B环上的氨基功能,如化合物12a所示.
- 发现化合物12a与异质位结合,影响SHIP2 L4循环动态.
- 12a (20-40μM) 通过增强Akt酸化,显著增加了老鼠肌管中的葡萄糖吸收.
- 12a表现出良好的Caco-2细胞透性.
结论:
- 极光化学型为开发类似药物SHIP2抑制剂提供了一个有前途的新支架.
- 化合物12a因其作用机制和细胞透性而显示出作为口服胰岛素敏感剂的化合物的潜力.
- 欧龙衍生物的进一步开发可能会导致新型治疗方法,用于治疗2型糖尿病等代谢障碍.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
170
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
170
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Sulfonylureas
200
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
200
Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


